For the full analysisinclusive of demographics, comorbidities, and social drivers of health data for the population, methodology, additional findings, limitations, and citationsyou can view the complete report on MedRxiv or directly within Truveta Studio
Ozempic je zatieno ime za semaglutid, lek iz klase agonista receptora za GLP-1
Pharmaceuticals GLP-1 Receptor Agonist Market GLP-1 Receptor Agonist Market Size, Trends, Share, Growth, and Regional Forecast, 2026 to 2033 GLP-1 Receptor Agonist Market by Product (Ozempic, Wegovy, Rybelsus, Victoza, Zepbound, Saxenda, Trulicity, Mounjaro, Others), Indication (Type 2 Diabetes mellitus, Obesity, Others), Route of Administration (Parenteral, Oral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Analysis from 2026 to 2033 December 2025 210 Pages Author : Abhijeet Surwase GLP-1 Receptor Agonist Market Share and Trends Analysis The global GLP-1 receptor agonist market size is estimated to grow from US$ 74.4 billion in 2026 to US$ 232.8 billion by 2033
10.1136/bmj.l4898 [DOI] [PubMed] [Google Scholar] Taheri S., Saffaei A., Amani B., Akbarzadeh A., Peiravian F., Yousefi N
Cardiovascular and malignancy screening are standard practice before initiation
In STEP-1, cholelithiasis-related events occurred in 2.6% of semaglutide patients versus 1.2% in the placebo group [1]
